# Phase II Trial of Continuation Therapy in Advanced NSCLC

> **NCT03083808** · PHASE2 · COMPLETED · sponsor: **Greg Durm, MD** · enrollment: 35 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03083808
- **Lead sponsor:** Greg Durm, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2021-12-14
- **Final completion:** 2022-03-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083808, "Phase II Trial of Continuation Therapy in Advanced NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03083808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*